Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin

Henriette Skribek, Rita Otvos, Emilie Flaberg, Noemi Nagy, Laszlo Markasz, Staffan Eksborg, T. Masszi, Andras Kozma, Emma Adam, A. Miseta, Eva Klein, Laszlo Szekely

Research output: Article

9 Citations (Scopus)

Abstract

Objective: To generate a comprehensive map of the drug sensitivity of chronic lymphoid leukemia cells (CLL) using a newly developed in vitro drug-sensitivity assay based on automated evaluation of cell viability on single-cell level. Materials and Methods: Primary CLL cells from 77 patients were tested using automated digital fluorescence microscopy. The effect of 27 frequently used chemotherapeutic agents was measured in short-term fluorescence survival assay. To avoid typical in vitro artifacts such as growth factor depletion and oxidative damage, the cell were cultured in a novel, total human blood lysate-based medium (OmniSanguine) in order to preserve the composition of growth factor flora and redox conditions of the in vivo environment. Results: CLL cells from different patients showed considerable heterogeneity in their drug-sensitivity patterns. This pattern was stable even after in vitro activation of cell proliferation. Half of the samples were sensitive to fludarabine and chlorambucil. Daunorubicin was the most potent drug. It was effective in 75 of 77 cases. In addition, daunorubicin and prednisolone showed a strong synergistic effect. Conclusions: We suggest that the combination of low-dose daunorubicin and prednisolone might be an additional treatment option for therapy-resistant cases of CLL.

Original languageEnglish
Pages (from-to)1219-1230
Number of pages12
JournalExperimental Hematology
Volume38
Issue number12
DOIs
Publication statusPublished - dec. 2010

Fingerprint

Lymphoid Leukemia
Epirubicin
Daunorubicin
Prednisolone
Doxorubicin
Lymphocytes
Pharmaceutical Preparations
Intercellular Signaling Peptides and Proteins
Chlorambucil
Fluorescence Microscopy
Artifacts
Oxidation-Reduction
Cultured Cells
Cell Survival
Fluorescence
Cell Proliferation
Survival
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Molecular Biology
  • Hematology

Cite this

Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. / Skribek, Henriette; Otvos, Rita; Flaberg, Emilie; Nagy, Noemi; Markasz, Laszlo; Eksborg, Staffan; Masszi, T.; Kozma, Andras; Adam, Emma; Miseta, A.; Klein, Eva; Szekely, Laszlo.

In: Experimental Hematology, Vol. 38, No. 12, 12.2010, p. 1219-1230.

Research output: Article

Skribek, Henriette ; Otvos, Rita ; Flaberg, Emilie ; Nagy, Noemi ; Markasz, Laszlo ; Eksborg, Staffan ; Masszi, T. ; Kozma, Andras ; Adam, Emma ; Miseta, A. ; Klein, Eva ; Szekely, Laszlo. / Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. In: Experimental Hematology. 2010 ; Vol. 38, No. 12. pp. 1219-1230.
@article{2f9a022d6ec74137af33fb6f54f9db45,
title = "Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin",
abstract = "Objective: To generate a comprehensive map of the drug sensitivity of chronic lymphoid leukemia cells (CLL) using a newly developed in vitro drug-sensitivity assay based on automated evaluation of cell viability on single-cell level. Materials and Methods: Primary CLL cells from 77 patients were tested using automated digital fluorescence microscopy. The effect of 27 frequently used chemotherapeutic agents was measured in short-term fluorescence survival assay. To avoid typical in vitro artifacts such as growth factor depletion and oxidative damage, the cell were cultured in a novel, total human blood lysate-based medium (OmniSanguine) in order to preserve the composition of growth factor flora and redox conditions of the in vivo environment. Results: CLL cells from different patients showed considerable heterogeneity in their drug-sensitivity patterns. This pattern was stable even after in vitro activation of cell proliferation. Half of the samples were sensitive to fludarabine and chlorambucil. Daunorubicin was the most potent drug. It was effective in 75 of 77 cases. In addition, daunorubicin and prednisolone showed a strong synergistic effect. Conclusions: We suggest that the combination of low-dose daunorubicin and prednisolone might be an additional treatment option for therapy-resistant cases of CLL.",
author = "Henriette Skribek and Rita Otvos and Emilie Flaberg and Noemi Nagy and Laszlo Markasz and Staffan Eksborg and T. Masszi and Andras Kozma and Emma Adam and A. Miseta and Eva Klein and Laszlo Szekely",
year = "2010",
month = "12",
doi = "10.1016/j.exphem.2010.09.001",
language = "English",
volume = "38",
pages = "1219--1230",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin

AU - Skribek, Henriette

AU - Otvos, Rita

AU - Flaberg, Emilie

AU - Nagy, Noemi

AU - Markasz, Laszlo

AU - Eksborg, Staffan

AU - Masszi, T.

AU - Kozma, Andras

AU - Adam, Emma

AU - Miseta, A.

AU - Klein, Eva

AU - Szekely, Laszlo

PY - 2010/12

Y1 - 2010/12

N2 - Objective: To generate a comprehensive map of the drug sensitivity of chronic lymphoid leukemia cells (CLL) using a newly developed in vitro drug-sensitivity assay based on automated evaluation of cell viability on single-cell level. Materials and Methods: Primary CLL cells from 77 patients were tested using automated digital fluorescence microscopy. The effect of 27 frequently used chemotherapeutic agents was measured in short-term fluorescence survival assay. To avoid typical in vitro artifacts such as growth factor depletion and oxidative damage, the cell were cultured in a novel, total human blood lysate-based medium (OmniSanguine) in order to preserve the composition of growth factor flora and redox conditions of the in vivo environment. Results: CLL cells from different patients showed considerable heterogeneity in their drug-sensitivity patterns. This pattern was stable even after in vitro activation of cell proliferation. Half of the samples were sensitive to fludarabine and chlorambucil. Daunorubicin was the most potent drug. It was effective in 75 of 77 cases. In addition, daunorubicin and prednisolone showed a strong synergistic effect. Conclusions: We suggest that the combination of low-dose daunorubicin and prednisolone might be an additional treatment option for therapy-resistant cases of CLL.

AB - Objective: To generate a comprehensive map of the drug sensitivity of chronic lymphoid leukemia cells (CLL) using a newly developed in vitro drug-sensitivity assay based on automated evaluation of cell viability on single-cell level. Materials and Methods: Primary CLL cells from 77 patients were tested using automated digital fluorescence microscopy. The effect of 27 frequently used chemotherapeutic agents was measured in short-term fluorescence survival assay. To avoid typical in vitro artifacts such as growth factor depletion and oxidative damage, the cell were cultured in a novel, total human blood lysate-based medium (OmniSanguine) in order to preserve the composition of growth factor flora and redox conditions of the in vivo environment. Results: CLL cells from different patients showed considerable heterogeneity in their drug-sensitivity patterns. This pattern was stable even after in vitro activation of cell proliferation. Half of the samples were sensitive to fludarabine and chlorambucil. Daunorubicin was the most potent drug. It was effective in 75 of 77 cases. In addition, daunorubicin and prednisolone showed a strong synergistic effect. Conclusions: We suggest that the combination of low-dose daunorubicin and prednisolone might be an additional treatment option for therapy-resistant cases of CLL.

UR - http://www.scopus.com/inward/record.url?scp=78549233335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549233335&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2010.09.001

DO - 10.1016/j.exphem.2010.09.001

M3 - Article

C2 - 20837094

AN - SCOPUS:78549233335

VL - 38

SP - 1219

EP - 1230

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 12

ER -